Serhii Tokarev, co-founder of SET University, discusses the Generation H programme, which is now open to teams from abroad
The third round of applications has opened in Ukraine for Generation H, a HealthTech programme for MedTech startups that has gone international this year. Teams and founders from abroad are now eligible to participate. The grand prize is UAH 650,000 in funding. This was announced by Serhii Tokarev, co-founder of SET University and founder of the Tokarev Foundation.
The decision to scale up is linked to the rapid growth of the HealthTech market, which has already exceeded $300 billion. In addition, AI technologies in medicine are growing by 35–40% annually.
Generation H 3.0: what participants can expect
The accelerator programme is designed for startups with a ready MVP or a product that has already generated initial sales and is ready to scale. All participants will receive personalised mentoring, workshops on entering international markets, business model validation, individual matchmaking with investors, product crash tests, and support with regulatory issues.
The programme will be held in a hybrid format. Participants from abroad will be able to work online without relocating. The best startup will receive UAH 650,000 in investment. Applications must be submitted by 24 May via the SET University website.
Practitioners with real-world industry experience have been invited to serve as mentors. Among them are:
- Volodymyr Nerubenko — co-founder of TerraLab and the Liki24 Foundation
- Fergus O’Dea — Vice President of Commercial Operations at FIRE1
- Alexa Sinyacheva — co-founder of Moeco and Techstars mentor
- Eric Henry — Senior Counsel for FDA Compliance at King & Spalding
Achievements of previous seasons of the accelerator programme
The two previous cohorts of Generation H included 30 projects, whose graduates have attracted over UAH 11 million in investment. In addition, they have won competitions such as EIT Jumpstarter, IT Arena, and Google for Startups, and have expanded into the US and European markets. Among them:
- M Shield — the development of a drug to prevent the spread of metastases
- TAYRA.AI — an AI medical scribe that automatically structures doctors’ consultations
- Ovul — the world’s first AI device for tracking fertility through saliva analysis
“I invest in the HealthTech sector because this is where you can clearly see the shortest path from technology to improving quality of life. But a high-quality product alone is not enough. You also need to understand regulations, decision-making cycles, and medical logic. That is why acceleration and mentorship are essential,” notes Serhii Tokarev.
